Just weeks after getting its first NDA in — and grabbing priority review from the FDA in the process — BridgeBio says it’s lined up a second potential speedy approval for the portfolio.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,